Clinical Trials

“Clinical trials are  the best way that APCaRI scientists can move new discoveries from the laboratory to the clinic.”

 

APCaRI is working in a new study to:

1. Find new tests in blood, urine, semen, or biopsy (or surgery) samples that can tell if a patient has prostate cancer.

2. Find tests that can identify aggressive cancers.

 

We need you!

Join the Study
Find Cancer Trials in Alberta

To discover these tests, blood, urine,  semen and clinical information from close to 4000 men are required. We plan to enroll patients over a period of 5 years in Calgary and Edmonton.

In Calgary, recruitment will occur at the Prostate Cancer Centre and Tom Baker Cancer Centre. In addition, participants may join the study by contacting the Calgary study coordinator at 403-943-8942.

In Edmonton, recruitment will occur at the Northern Alberta Urology Centre and Cross Cancer Institute. In addition, participants may join the study by contacting the Edmonton study coordinator at 780-407-5914.

Ask your doctor if you are eligible to participate in the study!

Submit your contact information to Participate

Download the Alberta Prostate Registry and Biorepository Information Brochure.

Download the Alberta Prostate Cancer Registry and Biorepository Information Brochure.

 

 

Clinical trials are one of the best ways to test new methods to diagnose, treat, manage, and prevent cancer, to ultimately deliver the best treatment and care possible to Albertans facing cancer.

Cancer Control Alberta reduces the impact of cancer on all Albertans and provides expert care and support for patients from their first symptom to survivorship. Supporting world-class research are two specialized teams that operate within the Clinical Trials Units at the Cross Cancer Institute and the Tom Baker Cancer Centre.  Each team provides well-trained staff and comprehensive services to researchers who are conducting clinical trials. In addition to the cancer centres, The Prostate Cancer Centre in Calgary and the Northern Alberta Urology Centre in Edmonton are testing advances in diagnosis and treatment to improve quality of life and work towards a cure for prostate cancer.

Find Clinical Trials in Alberta

Dr. Nawaid Usmani and team receive funding for their PRIME study!

The PRIME Study – Prevention and Intervention for MEtabolic syndrome:

Androgen deprivation therapy (ADT), and newer manipulations of androgen receptor signaling have improved outcomes for advanced prostate cancer (PCa) patients.  The toxicities of ADT are many, including an increased risk of developing metabolic syndrome (MS; defined as at least 3 of: hyperglycemia; abdominal obesity; hypertriglyceridemia; reduced HDL cholesterol; and/or hypertension). MS is associated with an increased risk of diabetes, cardiovascular disease mortality, stroke mortality, and all-cause mortality.  The prevalence of MS in men receiving ADT is at least 50% and contributes to decreased quality of life and increased non-cancer-related mortality.  Metformin holds promise as a countermeasure to MS development, and also has been shown to suppress PCa growth in pre-clinical models.

We hypothesize that the addition of metformin to ADT will reduce the rates of MS in men with advanced PCa, diminishing important toxicities of a therapy universally used in advanced disease.

We propose a double-blind, randomized phase III study of metformin or placebo in men with PCa starting intermittent ADT. The primary endpoint is the difference in MS rates at 1 year.  Other aims include evaluation of the influence of metformin on: individual MS components at additional time points; mean serum insulin levels and measures of insulin resistance; weight and quality of life.

A finding that metformin reduces MS incidence and/or has other benefits would change practice, as it would provide a practical and inexpensive strategy to reduce toxicity of an intervention employed in most men with advanced PCa.

- Catalina Vasquez

Our International Network of Partners

Meeting these ambitious goals will not be possible without the committed engagement of our many partners across Alberta, Canada and the World. Learn more about our Partners.